[{"orgOrder":0,"company":"Harrow","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Moxifloxacin Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Harrow \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Harrow \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Moxifloxacin HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

                          Product Name : Vigamox

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 31, 2023

                          Lead Product(s) : Moxifloxacin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Ophthalmology Consultants, Ltd.

                          Country arrow
                          OPRD
                          Not Confirmed

                          Ophthalmology Consultants, Ltd.

                          Country arrow
                          OPRD
                          Not Confirmed

                          Details : Vigamox is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 19, 2011

                          Lead Product(s) : Moxifloxacin Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Ophthalmology Associates, St Louis | Bausch & Lomb Incorporated

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OPRD
                          Not Confirmed
                          OPRD
                          Not Confirmed

                          Details : AL-15469A is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Bacterial.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 11, 2010

                          Lead Product(s) : Moxifloxacin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank